vs
Cellebrite DI Ltd.（CLBT）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Cellebrite DI Ltd.的季度营收约是REPLIGEN CORP的1.5倍（$292.2M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -103.5%，领先110.2%），Cellebrite DI Ltd.自由现金流更多（$60.8M vs $17.6M），过去两年Cellebrite DI Ltd.的营收复合增速更高（72.8% vs 14.4%）
Cellebrite DI Ltd.是一家总部位于以色列佩塔提克瓦的数字取证企业，为执法机构、企业及服务供应商提供数字数据的采集、审阅、分析与管理工具，旗下核心产品系列为Cellebrite UFED。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CLBT vs RGEN — 直观对比
营收规模更大
CLBT
是对方的1.5倍
$197.9M
净利率更高
RGEN
高出110.2%
-103.5%
自由现金流更多
CLBT
多$43.3M
$17.6M
两年增速更快
CLBT
近两年复合增速
14.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $292.2M | $197.9M |
| 净利润 | $-302.3M | $13.3M |
| 毛利率 | 84.6% | 52.5% |
| 营业利润率 | 14.1% | 9.0% |
| 净利率 | -103.5% | 6.7% |
| 营收同比 | — | 13.6% |
| 净利润同比 | — | 143.9% |
| 每股收益（稀释后） | $-1.50 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLBTRGEN
| Q4 25 | — | $197.9M | ||
| Q3 25 | $292.2M | $188.8M | ||
| Q2 25 | $220.8M | $182.4M | ||
| Q1 25 | $89.6M | $169.2M | ||
| Q4 24 | — | $174.1M | ||
| Q3 24 | $232.1M | $154.9M | ||
| Q2 24 | $185.3M | $154.1M | ||
| Q1 24 | $71.2M | $151.3M |
净利润CLBTRGEN
| Q4 25 | — | $13.3M | ||
| Q3 25 | $-302.3M | $14.9M | ||
| Q2 25 | $36.9M | $14.9M | ||
| Q1 25 | $-71.4M | $5.8M | ||
| Q4 24 | — | $-30.3M | ||
| Q3 24 | — | $-654.0K | ||
| Q2 24 | $-95.2M | $3.3M | ||
| Q1 24 | $-40.6M | $2.1M |
毛利率CLBTRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | 84.6% | 53.2% | ||
| Q2 25 | 84.1% | 50.0% | ||
| Q1 25 | 85.2% | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | 83.5% | 50.0% | ||
| Q2 24 | 84.1% | 49.8% | ||
| Q1 24 | 82.6% | 49.5% |
营业利润率CLBTRGEN
| Q4 25 | — | 9.0% | ||
| Q3 25 | 14.1% | 8.9% | ||
| Q2 25 | 12.1% | 7.6% | ||
| Q1 25 | 10.3% | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | 7.9% | -5.1% | ||
| Q2 24 | 11.7% | 1.0% | ||
| Q1 24 | 0.2% | 1.3% |
净利率CLBTRGEN
| Q4 25 | — | 6.7% | ||
| Q3 25 | -103.5% | 7.9% | ||
| Q2 25 | 16.7% | 8.2% | ||
| Q1 25 | -79.7% | 3.4% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | — | -0.4% | ||
| Q2 24 | -51.4% | 2.2% | ||
| Q1 24 | -57.0% | 1.4% |
每股收益（稀释后）CLBTRGEN
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-1.50 | $0.26 | ||
| Q2 25 | $0.15 | $0.26 | ||
| Q1 25 | $-0.36 | $0.10 | ||
| Q4 24 | — | $-0.55 | ||
| Q3 24 | $-0.35 | $-0.01 | ||
| Q2 24 | $-0.48 | $0.06 | ||
| Q1 24 | $-0.21 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $191.7M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $336.0M | $2.1B |
| 总资产 | $690.6M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CLBTRGEN
| Q4 25 | — | $767.6M | ||
| Q3 25 | $191.7M | $748.7M | ||
| Q2 25 | $326.1M | $708.9M | ||
| Q1 25 | $191.7M | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | $189.5M | $784.0M | ||
| Q2 24 | $178.6M | $809.1M | ||
| Q1 24 | $189.5M | $780.6M |
总债务CLBTRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CLBTRGEN
| Q4 25 | — | $2.1B | ||
| Q3 25 | $336.0M | $2.1B | ||
| Q2 25 | $408.4M | $2.1B | ||
| Q1 25 | $336.0M | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $34.2M | $2.0B | ||
| Q2 24 | $-40.2M | $2.0B | ||
| Q1 24 | $34.2M | $2.0B |
总资产CLBTRGEN
| Q4 25 | — | $2.9B | ||
| Q3 25 | $690.6M | $2.9B | ||
| Q2 25 | $787.4M | $2.9B | ||
| Q1 25 | $690.6M | $2.9B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | $532.9M | $2.8B | ||
| Q2 24 | $556.6M | $2.9B | ||
| Q1 24 | $532.9M | $2.8B |
负债/权益比CLBTRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $60.8M | $17.6M |
| 自由现金流率自由现金流/营收 | 20.8% | 8.9% |
| 资本支出强度资本支出/营收 | 1.8% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $172.1M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CLBTRGEN
| Q4 25 | — | $25.7M | ||
| Q3 25 | $66.2M | $48.1M | ||
| Q2 25 | $53.5M | $28.6M | ||
| Q1 25 | $10.0M | $15.0M | ||
| Q4 24 | — | $39.2M | ||
| Q3 24 | $58.2M | $49.3M | ||
| Q2 24 | $24.6M | $42.2M | ||
| Q1 24 | $12.5M | $44.7M |
自由现金流CLBTRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | $60.8M | $43.4M | ||
| Q2 25 | $47.5M | $21.5M | ||
| Q1 25 | $8.5M | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | $55.3M | $42.3M | ||
| Q2 24 | $21.0M | $37.4M | ||
| Q1 24 | $11.4M | $36.4M |
自由现金流率CLBTRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | 20.8% | 23.0% | ||
| Q2 25 | 21.5% | 11.8% | ||
| Q1 25 | 9.5% | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | 23.8% | 27.3% | ||
| Q2 24 | 11.3% | 24.3% | ||
| Q1 24 | 16.0% | 24.0% |
资本支出强度CLBTRGEN
| Q4 25 | — | 4.1% | ||
| Q3 25 | 1.8% | 2.5% | ||
| Q2 25 | 2.7% | 3.9% | ||
| Q1 25 | 1.7% | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | 1.3% | 4.5% | ||
| Q2 24 | 1.9% | 3.1% | ||
| Q1 24 | 1.5% | 5.5% |
现金转化率CLBTRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | 1.45× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLBT
| Subscription services | $197.2M | 67% |
| Term-license | $60.8M | 21% |
| Professional services | $23.2M | 8% |
| Other non-recurring | $11.0M | 4% |
RGEN
暂无分部数据
